Kinnevik AB publ Boosts Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Kinnevik AB publ lifted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 12.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,434,171 shares of the company's stock after buying an additional 1,528,503 shares during the period. Recursion Pharmaceuticals comprises about 100.0% of Kinnevik AB publ's investment portfolio, making the stock its largest holding. Kinnevik AB publ owned 3.34% of Recursion Pharmaceuticals worth $71,067,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Brighton Jones LLC boosted its position in Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after purchasing an additional 6,699 shares during the last quarter. Private Advisor Group LLC boosted its position in Recursion Pharmaceuticals by 103.8% during the fourth quarter. Private Advisor Group LLC now owns 31,427 shares of the company's stock valued at $212,000 after purchasing an additional 16,008 shares during the last quarter. IFP Advisors Inc boosted its position in Recursion Pharmaceuticals by 170.4% during the fourth quarter. IFP Advisors Inc now owns 11,831 shares of the company's stock valued at $80,000 after purchasing an additional 7,455 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in Recursion Pharmaceuticals during the fourth quarter valued at approximately $163,000. Finally, QRG Capital Management Inc. boosted its position in Recursion Pharmaceuticals by 43.8% during the fourth quarter. QRG Capital Management Inc. now owns 26,271 shares of the company's stock valued at $178,000 after purchasing an additional 8,008 shares during the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a research note on Thursday. They issued an "equal weight" rating and a $5.00 price objective on the stock. Needham & Company LLC dropped their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Recursion Pharmaceuticals currently has an average rating of "Hold" and a consensus price target of $7.00.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX traded up $0.05 on Friday, hitting $5.26. The company's stock had a trading volume of 16,582,108 shares, compared to its average volume of 16,022,744. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average of $4.84 and a two-hundred day moving average of $6.11. The firm has a market capitalization of $2.14 billion, a P/E ratio of -2.97 and a beta of 0.91. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. Recursion Pharmaceuticals's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.39) EPS. Research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.